Short Interest in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Grows By 23.7%

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) was the target of a large increase in short interest in December. As of December 31st, there was short interest totaling 6,044,599 shares, an increase of 23.7% from the December 15th total of 4,887,952 shares. Based on an average daily volume of 1,105,707 shares, the days-to-cover ratio is presently 5.5 days. Approximately 10.6% of the company’s stock are sold short. Approximately 10.6% of the company’s stock are sold short. Based on an average daily volume of 1,105,707 shares, the days-to-cover ratio is presently 5.5 days.

Structure Therapeutics Price Performance

Shares of GPCR stock traded up $3.62 during trading hours on Monday, reaching $88.64. 1,622,313 shares of the stock were exchanged, compared to its average volume of 1,083,169. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $94.90. The business’s fifty day moving average is $55.31 and its two-hundred day moving average is $34.24. The firm has a market capitalization of $5.38 billion, a P/E ratio of -72.66 and a beta of -2.05.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). As a group, equities research analysts predict that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of GPCR. E. Ohman J or Asset Management AB acquired a new stake in shares of Structure Therapeutics during the fourth quarter worth about $314,000. Gilbert & Cook Inc. purchased a new stake in Structure Therapeutics during the 4th quarter valued at approximately $395,000. JPMorgan Chase & Co. increased its holdings in shares of Structure Therapeutics by 37.0% in the third quarter. JPMorgan Chase & Co. now owns 58,148 shares of the company’s stock valued at $1,628,000 after purchasing an additional 15,706 shares during the period. Alyeska Investment Group L.P. acquired a new stake in shares of Structure Therapeutics during the third quarter worth $6,856,000. Finally, Paradigm Biocapital Advisors LP purchased a new position in Structure Therapeutics in the 3rd quarter valued at $10,440,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Stifel Nicolaus upped their price objective on Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Piper Sandler reissued an “overweight” rating on shares of Structure Therapeutics in a report on Tuesday, October 28th. Zacks Research downgraded Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, October 17th. BMO Capital Markets restated an “outperform” rating on shares of Structure Therapeutics in a research report on Tuesday, January 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $99.11.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.